Drug companies must do more for poor countries, conference is toldBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7416.642-c (Published 18 September 2003) Cite this as: BMJ 2003;327:642
- Lynn Eaton
Drugs companies need to think very carefully about trials carried out in the developing world, a leading expert on molecular medicine has warned a conference on the drug industry's future. And the industry should do more to address the need for medicines in the developing world, said another speaker.
David Weatherall, emeritus professor of medicine and former director of the Weatherall Institute of Molecular Medicine, Oxford University, was addressing a two day international conference on the future of the drug industry and its search for new medicines, held in London last week by the Royal Institute of International Affairs.
Research in developing countries could raise issues that may not be so high on the agenda in the developed world, he said, explaining that he had recently returned from a project in Asia …
Log in using your username and password
Log in through your institution
Sign up for a free trial